Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade (R)) to the biosimilar SB2 (Flixabi (R)) in inflammatory bowel disease patients - Fischer, Sven Moritz; Klenske, E.; Schmitt, H.; Vitali, Francesco; Hirschmann, S.; Koch, F.; Ramming, A.; Zundler, Sebastian; Nagore, D.; Uter, Wolfgang; Neurath, Markus; Atreya, Raja (2018)
EVALuna2:34075